Table 2 Characteristics of studies included in the systematic review
From: Immunity as a predictor of anti-malarial treatment failure: a systematic review
Study: author, year | Country (province) | Study design (n) | Age range (years) | Antigen (allele)—IgG seroprevalence | Antimalarial | Dosage | Follow-up (days) | Treatment failure (n/N) |
|---|---|---|---|---|---|---|---|---|
Van Geertruyden, 2009 [26] | Zambia (Copperbelt) | Randomized control trial (268) | 15–50 | AMA1b, MSP2(3D7), MSP2(FC27), VSA(E8B), VSA(A4), VSA f(HCD6) | AM + LM or SPf | AM + LM: 20 mg AM and 120 mg LM at 0, 8, 25, 36, 48 and 60 h; SP: 500 mg S and 25 mg P × 3 tablets as a single dose | 45 | 11% (30/268)h |
Mayxay, 2001 [27] | Thailand (Central Region) | Clinical efficacy study (80) | 24 (mean)a | RESAb—80% | AS or AS + AZ or AM + LMf | DNS | 28 | 50% (40/80)h |
Enevold, 2007 [25] | Tanzania (Dodoma Region) | Clinical efficacy study (100) | 0.5–<5 | AMA1(FVO)—75%, DBL2βPF13_0003(3D7)—85%, DBL4PFD1235W(3D7)—76%, EBA-175b—62%, MSP1b—85%, MSP3(FVO)—82%, CIDR1(3D7)—72%, GLURP-R0(FVO)—70%, GLURP-R2(FVO)—65%, VSA1c—82%, VSA2d —82%, Schizont Extract (F32)—95% | SP (n = 50) or AQ (n = 50) | SP; 25 mg/kg S and 1.25 mg/kg P once daily for 3 days; AQ: 10 mg/kg AQ once daily for 3 days | 28 | DNS |
Keh, 2012 [22] | Uganda (Central Region) | Clinical efficacy study (88) | 1–10 | AMA1(3D7)—63%, MSP1-19(FVO)—95%, MSP2(3D7)—87%, MSP3b—15%, GLURPR0(F32)—26%, GLURPR2(F32)—40% | AQ + SP (n = 88) | AQ + SP: 25 mg/kg AQ over 3 days (10, 10, 5 mg/kg) and 25 mg/kg S and 1.25 mg/kg P on day 1 | 63 | 11% (10/88) |
Mawili-Mboumba, 2003 [21] | Gabon (Moyen-Ogooué) | Clinical efficacy study (153) | 0.5–10 | MSP1Bl2(K1)—43%, MSP1 Bl2(RO33)—16%, MSP1 Bl2(MAD20)—10%, MSP1 Bl1—83% | AQ (n = 153) | AQ: 10 mg/kg per day for 3 days | 28 | 33% (51/153) |
Aubuoy, 2007 [23] | Gabon (Hauut-Ogooué) | Clinical efficacy study (232) | 0.5–10 | MSP1-19 e(Wellcome) | AQ (n = 118) or SP (n = 114) | AQ: 30 mg/kg AQ days 0 and 1; SP: 25 mg/kg S and 1.25 mg/kg P days 0 and 1 | 28 | AQ: 32% (38/118) SP: 14% (16/114) |
Diarra, 2012 [20] | Burkina-Faso (Bazega) | Clinical efficacy study (284) | 0.5–15 | MSP1-19b, MSP3b, GLURPb,e | CQ (n = 195) or SP (n = 53) | CQ: 25 mg/kg CQ over 3 days (10, 10, 5 mg/kg); SP: 500 mg S and 25 mg Pg | 28 | CQ: 62% (33/53) SP: 92% (179/195) |
Pinder, 2006 [24] | The Gambia (Kerewan) | Clinical efficacy study (46) | 1–10 | AMA1(FVO)—76%, MSP1-19(Wellcome)—80% | CQ (n = 46) | CQ: 25 mg/kg over 3 days (10, 10, 5 mg/kg) | 28 | 36% (17/46) |